Scripps Florida Logo

The Kissil Laboratory

Publications

Cui, Y., Groth, S., Carlstedt, A., Sperka, T., Riecken, L.B., Troutman, S., Kissil, J.L., Jin, H. and Morrison, H. “The NF2 tumor suppressor merlin interacts with RasGAP to negatively regulate Ras”. Oncogene, July 19, 2019. PMCID: PMC6756068 [PubMed]

Kota, S., Hou, S., Guerrant, W., Madoux, F., Troutman, S., Fernandez-Vega, V., Alekseeva, N., Madala, N., Scampavia, L., Kissil, J.L.# and Spicer, T.P.# (#corresponding authors). “A novel 3-dimensional high throughput screening approach identifies inducers of a KRAS selective lethal phenotype”. Oncogene 37;4372-4384, 2018. PMCID: PMC6138545 [PubMed]

Lyons, J., Brubaker, D.K., Baldwin, K., Edwards, A., Boukhali, M., Strasser, S.D., Suarez-Lopez L., Lin, Y.J., Yajnik, V., Kissil, J.L., Haas, W., Lauffenburger, D.A. and Haigis, K.M. “Integrated in vivo multiomics analysis identifies p21-kinase signaling as a driver of colitis”. Science Signaling, 11(519):eaan3580, 2018. PMID: 29487189 [PubMed]

Chinthalapudi, K., Mandati, V., Zheng, J., Sharff A.J., Bricogne G., Griffin, P., Kissil, J.L., and Izard, T. “Lipid binding promotes the open conformation and tumor-suppressive activity of neurofibromin 2” Nature Communications 9(1):(1338), 2018. PMCID: PMC5889391 [PubMed]

 Moleirinho, S.; Hoxha, S.; Mandati, V.; Curtale, G.; Troutman, S.; Ehmer, U.; Kissil, J.L.  "Regulation of localization and function of the transcriptional co-activator YAP by angiomotin." Elife. 2017 May 3;6 pii: e23966. doi: 10.7554/eLife.23966. PMCID: PMC5415356 [PubMed]

Troutman, S.; Moleirinho, S.; Kota, S.; Nettles, K.; Fallahi, M.; Johnson, G.L.; Kissil, J.L. "Crizotinib inhibits NF2-associated schwannoma through inhibition of Focal Adhesion Kinase 1." Oncotarget, 7(34):54515-25, 2016. PMCID: PMC5342359 [PubMed]
   
Guerrant, W; Kota, S; Troutman, S; Mandati, V; Fallahi, M; Stemmer-Rachamimov, A; Kissil, J.L. “YAP Mediates Tumorigenesis in Neurofibromatosis Type 2 by Promoting Cell Survival and Proliferation through a COX-2-EGFR Signaling Axis”. Cancer Research, 2016 May 23. PMCID: PMC4911274 [PubMed]

Moleirinho, S.; Guerrant, W.; Kissil, J.L.  “The Angiomotins – From discovery to function.”  FEBS Lett. 2014 Feb 15. pii:S0014-5793(14)00125-2.  PMCID: PMC4112001 [PubMed]

Yi, C.; Shen, Z.; Stemmer-Rachamimov, A.; Dawany, N.; Troutman, S.; Showe, L.C.; Liu, Q.; Shimono, A.; Sudol, M.; Holmgren, L.; Stanger, B.Z. and Kissil, J.L. “The p130 isoform of angiomotin is required for Yap-mediated hepatic epithelial cell proliferation and tumorigenesis.”  Science Signal. 2013 Sep 3;6(291):ra77.  PMCID: PMC4175526 [PubMed]

Zhou, C.; Troutman, S.; Maksimoska, J.; Liu, Q., Campbell, D.; Marmorstein, R. and Kissil, J.L. FRAX597, a small molecule inhibitor of the p21-activated kinases, inhibits tumorigenesis of NF2-associated schwannomas.”  J. Biol. Chem., 2013. PMCID: PMC379009 [PubMed]

Licciulli, S.; Avila, J.L.; Hanlon, L.; Troutman, S.; Cesaroni, M.; Keith B.; Simon, M.C.; Pure, E.; Radtke, F.; Capobianco, A.J. and Kissil, J.L. “Notch1 is required for Kras-induced lung adenocarcinoma and controls tumor cells survival via p53.” Cancer Res. 2013 Oct 1;73(19):5974-84.  PMCID: PMC3791518  [PubMed]

Avila, J.L. and Kissil, J.L. “Notch signaling in pancreatic cancer: oncogene or tumor suppressor?” Trends Mol Med. 2013 May; 19(5):320-7. PMCID: PMC3648591 [PubMed]


Avila, J.L.; Troutman, S.; Durham, A; and Kissil, J.L. “Notch1 is not required for acinar-to-ductal metaplasia in a model of Kras-induced pancreatic ductal adenocarcinoma." PLoS One. 2012;7(12):e52133. PMCID: PMC3526595 [PubMed]

Zhou, C; Licciulli, S.; Avila, J.L.; Cho, M.; Troutman, S.; Jiang, P.; Kossenkov, A.V.; Showe, L.C.; Liu, Q.; Vachani, A.; Albelda, S.M. and Kissil, J.L. “The Rac1 splice form Rac1b promotes K-ras-induced lung tumorigenesis.”  Oncogene. 2013 Feb 14;32(7):903-7.  PMCID: PMC3384754 [PubMed]

Caino, M.C.; Lopez-Haber, C.; Kissil, J.L.; Kazanietz, M.G. “Non-small cell lung carcinoma cell motility, rac activation and metastatic dissemination are mediated by protein kinase C epsilon. PLoS One.  2012;7(2):e31714. PMCID: PMC3288050  [PubMed]

Yi C.; Troutman S.; Fera D.; Stemmer-Rachamimov A.; Avila J.L.; Christian N.; Persson N.L.; Shimono A.; Speicher D.W.; Marmorstein R.; Holmgren L. and Kissil J.L. "A Tight Junction-Associated Merlin-Angiomotin Complex Mediates Merlin’s Regulation of Mitogenic Signaling and Tumor Suppressive Functions." Cancer Cell. 2011 Apr 12;19(4):527-40.  PMCID: PMC3075552 [PubMed]

Yi, C. and Kissil, J.L. "Merlin in organ size control and tumorigenesis: Hippo versus EGFR?" Genes Dev. 2010 Aug 15;24(16):1673-9. PMCID: PMC2922497 [PubMed]

Hanlon, L.; Avila, J.L.; Demarest, R.M.; Troutman, S.; Allen, M.; Ratti, F.; Rustgi, A.K.; Stanger, B.Z.; Radtke, F.; Adsay, V.; Long, F.; Capobianco, A.J. and Kissil, J.L. "Notch1 functions as a tumor suppressor in a model of K-ras-induced pancreatic ductal adenocarcinoma." Cancer Res. 2010 Jun 1;70(11):4280-6. PMCID: PMC2880196 [PubMed]

Licciulli, S; Kissil, J.L.  “WT1: a weak spot in KRAS-induced transformation.”  J Clin Invest. 2010 Nov;120(11):3804-7.  PMCID: PMC2965001  [PubMed]

Kissil, J.L.; Blakeley, J.O.; Ferner, R.E.; Huson, S.M.; Kalamarides, M.; Mautner, V.F.; McCormick, F; Morrison, H; Packer, R.; Ramesh, V.; Ratner, N; Rauen, K.A.; Stevenson, D.A.; Hunter-Schaedle, K.; North, K.  “What’s new in neurofibromatosis? Proceedings from the 2009 NF Conference: new frontiers.”  Am J Med Genet A.  2010 Feb;152A(2):269-83.  PMCID: PMC2818482  [PubMed]

Santos, A.M.; Jung, J.; Aziz, N.; Kissil, J.L.* and Puré E.* (*Equal contribution). “Targeting Fibroblast Activation Protein Inhibits Tumor Stromagenesis and Growth in Mice." J Clin Invest. 2009 Dec;119(12):3613-25. PMCID: PMC2786791 [PubMed]

Yi, C.; Wilker, E.W.; Yaffe, M.B.; Stemmer-Rachamimov, A. and Kissil, J.L. "Validation of the p21-activated kinases as targets for inhibition in neurofibromatosis type 2." Cancer Res. 2008 Oct 1;68(19):7932-7. PMCID: PMC2707059 [PubMed]

___________

Home
___________

Research
___________

Lab Members
___________

Lab Fun
___________

Publications
___________

Contact Us
___________

Support
___________